Avid Bioservices Inc (CDMO)

[biopharm]

Sean Bohen just jumped ship from Roche to join AZ in Sept 2015

"As previously communicated, the treatment and regulatory landscape in lung cancer is evolving," said Sean Bohen, the chief medical officer at AstraZeneca, in a statement. "We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development program focused primarily on novel combinations."

http://www.fiercebiotech.com/story/astrazeneca-hit-another-setback-durvalumab-disappoints-lung-cancer/2015-12-18

-------------------------------------------------

Sean Bohen:

Sean Bohen
Executive Vice President, Global Medicines Development, and Chief Medical Officer of AstraZeneca Pharmaceuticals

Dr Sean Bohen, M.D., Ph.D. is Executive Vice President, Global Medicines Development, and Chief Medical Officer of AstraZeneca Pharmaceuticals LP, responsible for leading the global late stage development organisation for both small molecules and biologics. As Chief Medical Officer, he is also responsible for patient safety across the entire AstraZeneca and MedImmune portfolio and is a member of AstraZeneca Senior Executive Team.
Prior to joining AstraZeneca in September 2015, he spent 12 years at Genentech Inc. in various senior leadership roles and played a pivotal role in the growth of its pipeline and bringing a number of new medicines to market. Latterly, he had oversight of the early development portfolio – bringing pipeline molecules from research through entry into late development, and spanning the therapeutic areas of oncology, rheumatology, respiratory, neurology, ophthalmology, cardiovascular, inflammatory bowel disease, endocrinology, and infectious disease. He led the clinical development of several medicines including the breast cancer drug Kadcyla, which he brought into the Genentech portfolio as team leader. Others include Rituxan and Ocrelizumab for the treatment of autoimmune diseases, Xolair for asthma and Erivedge for advanced basal cell carcinoma. He also steered activities to incorporate diagnostics into clinical programmes at all stages of development.

Dr Bohen was a Clinical Fellow and Clinical Instructor in Medical Oncology at Stanford University School of Medicine and a research associate at the Howard Hughes Medical Institute. A postdoctoral fellow at the National Cancer Institute, he also served as a member of the scientific advisory board of TaiMed Biologics, Inc.
He is a graduate of the University of Wisconsin-Madison and earned his doctorate in biochemistry and his medical degree at the University of California, San Francisco.

http://www.transceleratebiopharmainc.com/leaders/sean-bohen/

lots of key players are jumping ship elsewhere and going to where PS Targeting just may have found a home